Family of large biological molecules
POPULARITY
Categories
108 episodes with RNA
65 episodes with RNA
76 episodes with RNA
25 episodes with RNA
142 episodes with RNA
27 episodes with RNA
28 episodes with RNA
42 episodes with RNA
26 episodes with RNA
14 episodes with RNA
15 episodes with RNA
19 episodes with RNA
10 episodes with RNA
24 episodes with RNA
11 episodes with RNA
36 episodes with RNA
11 episodes with RNA
13 episodes with RNA
9 episodes with RNA
10 episodes with RNA
28 episodes with RNA
16 episodes with RNA
16 episodes with RNA
11 episodes with RNA
7 episodes with RNA
6 episodes with RNA
8 episodes with RNA
7 episodes with RNA
9 episodes with RNA
11 episodes with RNA
11 episodes with RNA
9 episodes with RNA
6 episodes with RNA
12 episodes with RNA
14 episodes with RNA
18 episodes with RNA
6 episodes with RNA
4 episodes with RNA
10 episodes with RNA
162 episodes with RNA
4 episodes with RNA
7 episodes with RNA
5 episodes with RNA
4 episodes with RNA
12 episodes with RNA
10 episodes with RNA
150 episodes with RNA
11 episodes with RNA
5 episodes with RNA
8 episodes with RNA
8 episodes with RNA
5 episodes with RNA
7 episodes with RNA
8 episodes with RNA
6 episodes with RNA
10 episodes with RNA
6 episodes with RNA
4 episodes with RNA
6 episodes with RNA
7 episodes with RNA
6 episodes with RNA
7 episodes with RNA
8 episodes with RNA
5 episodes with RNA
3 episodes with RNA
7 episodes with RNA
6 episodes with RNA
3 episodes with RNA
15 episodes with RNA
4 episodes with RNA
5 episodes with RNA
8 episodes with RNA
4 episodes with RNA
5 episodes with RNA
7 episodes with RNA
8 episodes with RNA
8 episodes with RNA
3 episodes with RNA
7 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
7 episodes with RNA
8 episodes with RNA
7 episodes with RNA
10 episodes with RNA
10 episodes with RNA
10 episodes with RNA
9 episodes with RNA
6 episodes with RNA
7 episodes with RNA
19 episodes with RNA
5 episodes with RNA
14 episodes with RNA
5 episodes with RNA
3 episodes with RNA
5 episodes with RNA
3 episodes with RNA
4 episodes with RNA
10 episodes with RNA
6 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
5 episodes with RNA
4 episodes with RNA
5 episodes with RNA
5 episodes with RNA
5 episodes with RNA
7 episodes with RNA
10 episodes with RNA
10 episodes with RNA
9 episodes with RNA
3 episodes with RNA
12 episodes with RNA
6 episodes with RNA
3 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
2 episodes with RNA
3 episodes with RNA
3 episodes with RNA
8 episodes with RNA
5 episodes with RNA
5 episodes with RNA
4 episodes with RNA
3 episodes with RNA
4 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
6 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
4 episodes with RNA
3 episodes with RNA
8 episodes with RNA
3 episodes with RNA
3 episodes with RNA
2 episodes with RNA
4 episodes with RNA
3 episodes with RNA
Witam Państwa, nazywam się Jarosław Drożdż, pracuję w Centralnym Szpitalu Klinicznym Uniwersytetu Medycznego w Łodzi, skąd nagrywam podcast Kardio Know-How. W tym odcinku rozpoczynam kontynuuję omawianie doniesień z tegorocznego kongresu AHA.Przeanalizowałem ponownie prezentacje z AHA 2025 i na drugim miejscu najważniejszych przełomów stawiam nowoczesne terapie lipidowe oparte na mRNA i edycji genów. Choć kardiologia wciąż opiera się głównie na klasycznej farmakoterapii, pojawiają się już u nas technologie znane z onkologii — przeciwciała monoklonalne i terapie oparte na RNA. W Polsce mamy alirokumab i inklisiran w programie B.101, a 27 listopada odbędzie się webinar z prof. Chlebusem nt. nowego otwarcia programu (link: https://sanofi.zoom.us/j/92476088795?pwd=DzcZmFDH7j2PzjQg3tZYuejpMNilmz.1). Pierwszą część stanowi Olezarsen z badań CORE-TIMI 72 — lek działający na mRNA apoC-III, obniżający TG nawet o 70% i redukujący ryzyko ostrego zapalenia trzustki o 85%. Nie efekty kliniczne, lecz sama nowa koncepcja terapii mRNA jest tu dla mnie kluczowa, choć aktualne badania pokazały nieoczekiwany wzrost LDL o ok. 50%. Mechanizm Olezarsenu opiera się na antysensownym oligonukleotydzie GalNAc3 kierowanym do hepatocytów i degradacji mRNA APOC3, co derepresjonuje lipazę lipoproteinową i przyspiesza klirens TG. Wyniki wraz z udziałem prof. Banacha opublikowano w NEJM: https://www.nejm.org/doi/abs/10.1056/NEJMoa2512761 oraz wcześniejsze dane: https://www.nejm.org/doi/full/10.1056/NEJMoa2507227. Drugą częścią nowości jest edycja genu ANGPTL3 — białka regulującego metabolizm lipidów, którego naturalne warianty utraty funkcji obniżają LDL i TG. Preparat CTX310 zawiera CRISPR-Cas9 zamknięty w nanocząsteczkach lipidowych i w badaniu fazy I (rok obserwacji) wykazał przede wszystkim bezpieczeństwo stosowania. To początek fascynującej drogi, która może w przyszłości doprowadzić do trwałego obniżania lipidów jednorazową terapią genową. Najnowsze doniesienia NEJM sugerują, że era leczenia aterogenezy poprzez edycję genów właśnie się rozpoczyna (https://www.nejm.org/doi/10.1056/NEJMoa2511778).Szczegółowy TRANSKRYPT do odcinka.Podcast jest przeznaczony wyłącznie dla osób z profesjonalnym wykształceniem medycznym.
Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, which led to a significant drop in their stock value. This scenario underscores the complexities of navigating clinical trial outcomes while pursuing breakthroughs in treating challenging diseases like sickle cell.Arrowhead Pharmaceuticals has marked a significant milestone with the FDA's approval of Plozasiran. This achievement not only marks Arrowhead's entry into the commercial sector but also highlights the competitive dynamics within biotech, as companies like Ionis Pharmaceuticals vie for market dominance with innovative therapies. Further strengthening its position, Arrowhead also received FDA approval for Redemplo, a siRNA-based therapeutic for rare genetic metabolic disorders. Despite facing volatility due to safety concerns in its partnership with Sarepta Therapeutics, this approval underscores RNA interference therapies' potential in precision medicine.In corporate strategy news, Alkermes is making moves to acquire Avadel Pharmaceuticals, offering up to $2.37 billion and overshadowing a competing bid from Lundbeck. Such acquisitions are part of a broader trend of consolidation in the industry aimed at expanding portfolios and market reach. Avadel's decision to accept Alkermes' revised offer over Lundbeck's bid highlights ongoing consolidation trends as companies expand their portfolios in competitive markets like narcolepsy drugs.On the investment front, Celltrion has committed $478 million to upgrade a U.S. manufacturing facility acquired from Eli Lilly. This expansion is crucial for increasing manufacturing capabilities within the biosimilars sector, where demand for cost-effective therapeutics is on the rise. Additionally, Celltrion's exploration beyond biosimilars with a potential $350 million deal involving Trioar's antibody platform demonstrates ambition to diversify its portfolio towards innovative biologics.Teva Pharmaceuticals is fostering innovation by inviting startups to tackle key challenges within biopharma through a global platform. This initiative reflects a growing trend toward open innovation and collaboration, seeking novel solutions to complex issues across research and development and manufacturing efficiencies.In regulatory news, the controversial $7.4 billion settlement plan involving the Sackler family and Purdue Pharma has received approval from a bankruptcy judge. This paves the way for Purdue's transformation into Knoa Pharma and highlights ongoing legal and ethical reckonings related to opioid liabilities within the industry.Cytokinetics remains committed to its independent path as it awaits FDA approval for its cardiovascular drug Aficamtem. The company's determination to commercialize without big pharma support reflects a trend where smaller biotech firms strive for autonomy while bringing first-in-class drugs to market.On an infectious disease front, Merck has demonstrated significant progress with its HIV treatment Islatravir in Phase 3 trials. This places Islatravir as a potential competitor against Gilead's Biktarvy, showcasing ongoing innovation within antiviral drug development.Additionally, Dexcom has gained clearance for its type 2 diabetes software integrating continuous glucose monitoring technology. This advancement exemplifies how digital health technologies are transforming chronic disease management bySupport the show
In this Mol Bio Minutes episode, Thermo Fisher Scientific's Monika Jazdauskaitė dives into the versatile world of Recombinase Polymerase Amplification (RPA). Unlike PCR, RPA operates at a constant, low temperature (around 37–42°C), enabling fast, equipment-light workflows that are ideal for field diagnostics and decentralized labs. Monika explains how the method works and why RPA is emerging as a go-to technique for both DNA and RNA target detection.She highlights RPA's specificity, sensitivity, and robustness against common inhibitors like ethanol and heparin, critical for applications like respiratory pathogen detection or low-quality sample inputs. Plus, she shares how RPA's gentle conditions and lyophilization compatibility make it a strong candidate for stabilizing next-generation sequencing (NGS) libraries, especially those with high GC content.Whether you're looking to simplify pathogen detection or streamline your sequencing prep, RPA offers a compelling alternative to traditional amplification. And with ready-to-use kits like the Invitrogen™ Lyo-ready RPA Kit, Thermo Fisher is helping researchers bring speed and stability to molecular workflows, all with no thermal cycler required. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.
Since the late 19th century, the concept of an "alien invasion" has been a recurring theme in literature, and also served as a kind of cultural pressure gauge—it reveals our fears about what might be lurking in the cosmos, as well as the everyday horrors of the human condition, forcing us to confront questions about our vulnerabilities, and our assumptions about intelligent life elsewhere in the universe. This week on The Micah Hanks Program, we lead off with a bit of discussion about the persistent rumors about the interstellar comet 3I/ATLAS, and whether its presence could actually bring the discussion about alien visitation out of fiction and into reality. Then, we shift our attention to the discussion about what a real alien invasion might entail, and what it could mean for life on Earth if it were ever to occur; would humanity be up to the task of defending against a cosmic threat from beyond the stars? Have you had a UFO/UAP sighting? Please consider reporting your sighting to the UAP Sightings Reporting System, a public resource for information about sightings of aerial phenomena. The story doesn't end here... become an X Subscriber and get access to even more weekly content and monthly specials. Want to advertise/sponsor The Micah Hanks Program? We have partnered with the AdvertiseCast to handle our advertising/sponsorship requests. If you would like to advertise with The Micah Hanks Program, all you have to do is click the link below to get started: AdvertiseCast: Advertise with The Micah Hanks Program Show Notes Below are links to stories and other content featured in this episode: NEWS: Grandest Thanksgiving Yet? 2025 Holiday To Cost Average American Up To $1,000 Pranksters bypass Louvre's security and sneak painting in Oldest sequenced RNA reveals details about a mammoth's final moments 40,000 years ago Archaeological breakthrough contradicts the timeline of human civilization 3I/ATLAS: The Harvard Scientist, Kim Kardashian and the Comet That Probably Isn't an Alien Spaceship INVADERS: Increased UFO Reports Aren't Aliens, But Earth Is Still Unprepared for an Alien Invasion Aliens may have stopped trying to contact humans because they simply got bored, Nasa scientist claims Mind of its own: Will "general AI" be like an alien invasion? BECOME AN X SUBSCRIBER AND GET EVEN MORE GREAT PODCASTS AND MONTHLY SPECIALS FROM MICAH HANKS. Sign up today and get access to the entire back catalog of The Micah Hanks Program, as well as "classic" episodes, weekly "additional editions" of the subscriber-only X Podcast, the monthly Enigmas specials, and much more. Like us on Facebook Follow @MicahHanks on X. Keep up with Micah and his work at micahhanks.com.
This episode is a double from my visit to the Advanced Lateral Flow Conference. Usability is Innovation: Atomo DiagnosticsAtomo Diagnostics set out more than a decade ago to solve a surprisingly human problem in diagnostics: complexity. Founder John Kelly describes how even the best rapid tests—validated in pristine lab environments—often fail when they reach the real world, where people have no training, and shaky instructions. That gap between laboratory precision and real-world usability has huge implications for reliability, trust, and ultimately regulatory approval.Atomo's core insight is simple: most errors in point-of-care testing aren't biological—they're behavioral. The accessories people use in the field (cheap pipettes, dropper bottles, uncalibrated parts) invite mistakes, and the more steps required, the higher the failure rate. Kelly and his team approached the problem the way a designer might: observe how real users behave, then engineer around human nature instead of fighting it.To validate their approach, they went straight to the source—literally to the community—conducting studies in Africa with low-literacy users who received only picture-based instructions. “If it needs a lot of explanation, it's probably not obvious,” Kelly notes. The goal: build a device that is self-explanatory and self-correcting.Their solution, the Pascal platform, integrates every accessory needed to run a test—lancet, blood collection, and buffer reagent—directly into one cartridge. Instead of multiple steps and parts, users simply collect, press, and go. Each step is interlocked to prevent mistakes; for instance, the reagent button won't activate until blood is correctly loaded. It's engineering that enforces proper sequence, eliminating user doubt and waste.Kelly describes how this design delivers the right volume, in the right order, every time—removing the “what if I did it wrong?” anxiety that undermines confidence in results. It's the difference between a reliable diagnostic and a false sense of security.Atomo's HIV self-test—registered with the World Health Organization and distributed across Australia, Europe, and the UK—has demonstrated greater than 99% concordance between trained and untrained users. The company also supports a blood-based pregnancy test (approved in Europe and Brazil) that detects earlier than urine tests, and they're now developing the world's first active syphilis test, capable of distinguishing between current and previously treated infections.What's equally smart is their business model flexibility. Recognizing that many manufacturers already have validated lateral flow cassettes on the market, Atomo developed a “clip-on” usability upgrade that integrates their collection and buffer technology without requiring full retooling or revalidation—a bridge between old workflows and modern design.Beyond infectious disease, Kelly sees growth in at-home wellness and chronic condition monitoring—everything from testosterone and thyroid tests to celiac screening. The platform's adaptability makes it attractive for home use and clinical trials alike. One example: a pharmaceutical partner using Atomo's device to monitor liver toxicity in patients remotely, reducing clinic visits from three times a week to “only when needed.” It's better for patients, cheaper for healthcare systems, and faster for research.The bigger story here is that usability is innovation. Kelly's approach turns workflow design into a driver of impact. Instead of chasing exotic chemistry, Atomo focused on reliability and trust—two things that ultimately decide whether a test makes it into people's hands.As diagnostics and healthcare move increasingly into the home, Atomo's design philosophy feels ahead of its time. If the pandemic taught us anything, it's that people can and will take responsibility for their health—if we give them tools that make sense.Pitch Competition Finalist: EAZEBIOI also sat down with Ying Chen, founder of EAZEBIO, one of the Innovation Award finalists. Her company's portable strip-based diagnostic platform combines CRISPR and AI to bring precision health to everyone, especially in low-resource settings.The Problem: Reactive HealthcareYing opens by explaining the fundamental flaw she sees in today's healthcare system—it's reactive. We wait for symptoms to become severe before acting. EAZEBIO's mission is to shift the paradigm toward proactive, precision healthcare, emphasizing early detection and personalized intervention. Her team focuses on diseases often overlooked at the root-cause level—metabolic, autoimmune, and cardiovascular conditions.Their aim is to bridge the gap between scientific breakthroughs and universal access, translating biomarker data into actionable health insights. As Ying puts it, “We hope proactive, personalized care can provide health equity for everyone, no matter where they live.”Ying's background is a blend of pediatrics, research science, and business—she holds both a PhD and an MBA. Her experience inspired her to adapt the power of CRISPR from the lab to the home.In their prototype for sepsis detection, EAZYBIO's system uses CRISPR to identify antimicrobial resistance genes—the genetic clues that reveal which pathogen is causing an infection. The test also detects human protein biomarkers, providing a two-layered view of infection and host response.Here's how it works:* The CRISPR complex acts like a molecular “scissor,” recognizing and cutting specific DNA or RNA sequences associated with infection.* These sequences are tagged with a cortisol-based reporter. When the CRISPR cut happens, cortisol is released.* The released cortisol binds to split reporter proteins, generating a visible signal on a lateral flow strip.* An AI-powered app then reads and interprets the signal into a semi-quantitative result.This approach achieves roughly 300x signal amplification compared to conventional lateral flow assays—crucial for fast, reliable results.Sepsis is notoriously time-sensitive; treatment delays of more than three hours can dramatically increase mortality. Ying emphasizes that EAZEBIO's platform could enable clinicians to identify pathogens and select the correct antibiotic within one hour—a potentially life-saving improvement.While sepsis is their initial target, the underlying platform is modular and scalable, enabling future multiplexing for 3–5 pathogens per test. Beyond acute disease, the same technology could support early cancer detection and wellness testing, making high-quality diagnostics as easy as a home pregnancy test.Ying speaks with humility about being a finalist at ALFC, but it's clear the recognition validates EAZEBIO's bold vision. The conference gave her valuable exposure to peers across R&D and manufacturing, as well as insights into where diagnostics are heading over the next decade.Her takeaway? Collaboration and accessibility matter just as much as innovation. “It's not just technology—it's about bringing care to everyone, whether they live in a big city or a rural village.” This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit cclifescience.substack.com
Ukłucie kleszcza, po którym hamburger staje się śmiertelny? Brzmi jak miejska legenda, ale zespół alfa-gal naprawdę zabija — i w tym odcinku opowiadamy o pierwszym potwierdzonym przypadku takiej śmierci w USA oraz o tym, jak ta dziwna alergia działa. A potem cofamy się o 39 tysięcy lat, żeby - dosłownie - zajrzeć do organizmu mamuta Yuki w chwili jego śmierci, bo naukowcom udało się odczytać jego RNA.Zachęcamy też do posłuchania naszej serii kryminalno-naukowej “Laboratorium zbrodni”, którą tworzymy we współpracy z Polskim Radiem. Znajdziecie ją m.in. na Spotify:https://open.spotify.com/show/5Sw33l0P1o2vDOErG6VGL2?si=b3068c6d99a34dacPolecamy również naszą serię poświęconą analizie teorii spiskowych. “Sekcja teorii spiskowych” dostępna jest na stronie Polskiego Radia, na Spotify i na YouTubie, bo to wideopodcast :) https://www.youtube.com/playlist?list=PLZTuUgCmeGG6cRigivWs3HvsZBIr2ZdRv https://open.spotify.com/show/60LKeNI1gjweNju6P7Bpsu Jeśli podobają Wam się nasze podcasty, rozważcie wsparcie nas na Patronite - dzięki Waszym wpłatom będziemy mogli utrzymać cotygodniowy rytm ukazywania się nowych odcinków: https://patronite.pl/crazynaukaJeśli wolisz jednorazowo postawić nam kawę, to super. Dzięki!
这是一期与《科技早知道》的串台节目2024 年的诺贝尔化学奖是颁给了三位在蛋白质结构预测和蛋白质设计领域作出开创性贡献的科学家。这标志着 AI 已经成为生命科学的核心工具 ，正在改变我们理解生命的方式和重塑药物研发的未来。我们今天的嘉宾是深圳湾实验室的周耀旗教授，他是这场变革的亲历者和推动者之一。他最初在学术界专注于蛋白质结构预测，后来他敏锐地意识到 RNA 领域的潜力与挑战，将研究方向转向 RNA 结构预测。现在他又走上创业之路，带领团队开发 以 RNA 为靶点的小分子药物，探索如何将基础研究真正转化为新的疗法。今天的节目我们聊一聊作为蛋白质结构预测工具的 AlphaFold3，它的突破与局限在哪里？RNA为什么是新一代药物的重要靶点？以及 AI 在新药研发中的作用究竟是什么?【本期人物】周耀旗，深圳湾实验室资深研究员，砺博生物科学创始人【时间戳】02:42 为什么蛋白质结构如此重要？解析蛋白结构是理解生命机器的关键05:47 蛋白质结构预测简史：基于模板 --> 碎片拼接 --> 二面角+距离预测14:26 「1+2=3」：AlphaFold 革命性飞跃的背后17:40 结构生物学家会不会被替代？聊聊 AlphaFold 还做不了的事23:26 RNA 结构预测为何更难？仅4个碱基，结构不稳定，已知数据稀缺29:24 蛋白质只是「提线木偶」，RNA 才是「操纵者」31:56 从靶向蛋白到靶向 RNA -- HIV蛋白酶抑制剂的成功和 KRAS 蛋白的「光滑锁眼」的难题35:49 靶向 RNA 药物的里程碑：首个靶向 RNA 的小分子药利司扑兰（Risdiplam）38:50 在缺乏结构数据的情况下，如何开发靶向 RNA 的药物？43:06 AI 在新药研发中的真实作用：是加速器，而非革命45:39 AI for Science：摆脱数据依赖，回归物理，寻找分子世界的「牛顿定律」
Send us a textGood morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Metsera's GLP-1 receptor agonist technology. This acquisition underscores the continuing trend of consolidation within the pharmaceutical industry, enhancing competitive market positioning and reflecting a broader quest for novel therapeutic solutions.Eli Lilly has entered into a $1.2 billion collaboration with Sangenebio to advance RNA interference (RNAi) therapeutics targeting metabolic diseases. This partnership marks a pivotal shift towards utilizing RNAi technology to silence disease-causing genes, representing significant progress in metabolic disease treatment. The focus on innovative delivery mechanisms and targeted interventions is critical for accelerating drug development and enhancing therapeutic efficacy.Onchilles Pharma's recent Series A1 funding round, securing $25 million, marks a notable advancement in oncology therapeutics. The company's focus on dual-action cancer biologics targeting the ELANE pathway offers promising insights into immune activation in solid tumors. This investment exemplifies the growing interest in biologic therapies that provide targeted cancer treatments, potentially leading to more effective options for patients.Regulatory advancements are also making headlines. Chongqing Precision Biotech has received approval for Pujiolunxi, a treatment for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), broadening therapeutic options for this challenging pediatric condition. Furthermore, Alembic Pharmaceuticals' generic version of Dasatinib tablets has gained FDA approval for Philadelphia chromosome-positive chronic myeloid leukemia, increasing accessibility to treatment.Several promising clinical trial results have emerged recently. Summit Therapeutics and Akeso Biopharma's Ivonescimab showed a 26% overall survival benefit in phase 3 trials for non-small-cell lung cancer. The potential of bispecific antibodies in combination therapies is gaining attention for its efficacy in difficult-to-treat cancers. Additionally, Regeneron's Dupixent has achieved phase 3 success in treating allergic fungal rhinosinusitis, reinforcing its role as a versatile treatment option across various inflammatory diseases.Advancements in cardiovascular therapeutics also continue to unfold. Merck & Co.'s Enlicitide Decanoate demonstrated over 50% LDL cholesterol reduction in a phase 3 study focused on atherosclerotic cardiovascular disease through PCSK9 inhibition. AstraZeneca's Baxdrostat showed significant blood pressure reduction in trials targeting treatment-resistant hypertension, highlighting the potential impact of aldosterone synthase inhibitors on cardiovascular health.The investment landscape remains robust with substantial fundraising activities such as Elephas Biosciences' $40 million Series B-2 for commercializing their live tumor profiling platform and Iambic's over $100 million series focused on AI-driven drug discovery. These investments underscore the industry's commitment to integrating advanced technologies like AI and live tumor profiling to enhance precision medicine capabilities.FDA regulatory updates are pivotal as well, notably with the decision to lift warning labels from hormone replacement therapy (HRT) products following an expert review that found previous warnings were based on misinformation regaSupport the show
BUFFALO, NY - November 10, 2025 – A new #research paper was #published in Oncotarget (Volume 16) on November 6, 2025, titled “Anti-DNA virus agent cidofovir - loaded green synthesized cerium oxide nanoparticles (Nanoceria): Nucleic acids (DNA and RNA) binding affinity and cytotoxicity effects.” In this study, led by Nahid Shahabadi from Razi University in Kermanshah, researchers developed an environmentally friendly approach to enhance the performance of cidofovir, a drug used to treat infections caused by DNA viruses. The work responds to the growing need for therapies that are safer, more effective, and better targeted. The research team developed a new compound by loading cidofovir onto green-synthesized cerium oxide nanoparticles (nanoceria), known as CDV-CeO2 NPs. This method combines the drug's antiviral and anticancer properties with the biological activity of nanoceria, which is known for its antioxidant, anti-inflammatory, and tumor-targeting effects. To avoid toxic chemicals, the nanoparticles were synthesized using quince fruit peel extract, making the process more sustainable and suitable for medical applications. Laboratory experiments showed that the CDV-CeO2 nanoparticles were significantly more effective at killing breast cancer cells than either cidofovir or cerium oxide nanoparticles alone. At the highest tested concentration, the new compound destroyed more than 97% of cancer cells, compared to 72% with cidofovir alone and 50% with nanoparticles alone. These findings suggest that the combined formulation enhances anticancer activity and may allow for lower drug doses with fewer side effects. To understand how these nanoparticles interact with genetic material, the team studied their binding to DNA and RNA, two key molecules involved in cancer development and viral replication. CDV-CeO2 nanoparticles showed strong binding affinity through two mechanisms: groove binding, which fits into natural curves of the genetic molecule strands, and intercalation, which inserts between base pairs. The nanoparticles formed stable complexes that responded to temperature, indicating reliable interactions in biological systems. “The novelty of this work lies in the innovative green synthesis method, the dual-functional therapeutic application, and the enhanced biological activity of the CDV-CeO2 NPs, which collectively position these nanoparticles as promising candidates for future cancer and antiviral therapies.” This research presents a potential new strategy for improving drug targeting and delivery using green nanotechnology. The approach could lead to more effective treatments for diseases such as breast cancer and infections caused by human papillomavirus (HPV) and other DNA viruses. However, further research, including animal and clinical studies, is needed to confirm the safety and long-term effectiveness of this treatment. Overall, this study represents a significant step toward combining natural materials with nanomedicine to create more efficient therapies. If supported by future research, CDV-CeO2 nanoparticles could offer a new generation of dual-action treatments. DOI - https://doi.org/10.18632/oncotarget.28774 Correspondence to - Nahid Shahabadi - nahidshahabadi@yahoo.com Abstract video - https://www.youtube.com/watch?v=Il9CsfgO2mU Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
From the mind of Vince Gilligan (Breaking Bad, Better Call Saul) comes the most original sci-fi premiere in years. In Episodes 1 & 2 of Pluribus (“We Is Us” and “Pirate Lady”), a rogue radio signal from deep space triggers a global transformation — and only one person is left unconnected: speculative romance author Carol Sturka, played by a powerhouse Rhea Seehorn.Brandon & Chanel dive into everything you missed:The alien RNA signal that infects the world via… saliva and donutsRhea Seehorn's brilliant performance as the reluctant resistanceThe arrival of Pirate Lady, a real-life version of Carol's book characterHelen's tragic death and what it means to “join” the hivemindSeizures triggered by Carol's emotions (that may have killed 11 million people
Upgrade your biology in 10 minutes with this week's rundown from Dave Asprey. This episode breaks down the six biggest stories in biohacking and health tech, from sleep hormones to mitochondrial rejuvenation, giving you the data you need to live longer, think faster, and perform at your peak. This episode covers: • The Melatonin Heart Warning Everyone Missed A major new study from the American Heart Association reveals that long-term melatonin users face nearly twice the risk of heart failure and 3.5 times higher hospitalization rates. Once considered a harmless sleep aid, melatonin's hormonal effects may disrupt cardiovascular recovery, testosterone, and blood pressure regulation when used nightly. The takeaway: melatonin is a short-term circadian reset tool, not a forever supplement. Source: American Heart Association — newsroom.heart.org/news/long-term-use-of-melatonin-supplements-to-support-sleep-may-have-negative-health-effects • Bryan Johnson's Extreme Microplastics Detox Biohacker Bryan Johnson shared lab-verified results showing an 85% reduction in microplastics in his semen after one year of daily 200°F dry saunas followed by ice packs on the groin. It's not peer reviewed yet, but it'ssparking global discussion about environmental toxins, fertility, and detoxification. Whether or not you follow his protocol, this study highlights how widespread microplastics have become and how heat, sweat, and smarter exposure control may help fight back. Source: New York Post — nypost.com/2025/10/23/health/biohacker-bryan-johnson-got-rid-of-85-of-microplastics-from-his-semen • Urolithin A: The Mitochondrial Molecule That Strengthens Immunity A peer-reviewed human trial published in Nature Aging found that four weeks of daily Urolithin A (Mitopure®) supplementation improved immune function in adults aged 45–70, increasing youthful CD8 T-cells, natural killer cells, and mitochondrial performance inside immune cells. By triggering mitophagy, your body's cleanup process for old mitochondria, Urolithin A enhances energy, resilience, and immune strength. It's the clearest evidence yet that we can modulate immune aging through mitochondrial renewal. Head to timeline.com/dave to get 10% off your first order. Source: BioSpace — biospace.com/press-releases/timeline-continues-to-build-the-most-clinically-researched-longevity-products-targeting-immune-brain-and-muscle-aging • Google's New AI Model That “Talks” to Cells Google DeepMind and Yale launched Cell2Sentence-Scale, an open-source AI model that lets scientists query cellular pathways in natural language. The system can predict how cells transition from healthy to cancerous states and identify molecular switches that might reverse those changes. It's compressing years of biology into days and democratizing research for small labs and independent scientists alike. Isn't AI a beautiful thing? Source: Google DeepMind — blog.google/technology/ai/google-gemma-ai-cancer-therapy-discovery • Omega-3s Calm the Brain and the Temper A massive new meta-analysis of randomized controlled trials shows omega-3 fatty acids (EPA and DHA) reduce aggression by up to 28%. That includes both reactive anger and planned aggression. By lowering neuroinflammation and stabilizing cell membranes, omega-3s appear to balance dopamine and serotonin, proving that healthy fats aren't just heart food, they're emotional regulators too. Source: Science Alert — sciencealert.com/one-dietary-supplement-was-shown-to-reduce-aggression-by-up-to-28 • Chronic Fatigue Syndrome Finally Gets a Biomarker For the first time, researchers have developed a blood test that accurately identifies chronic fatigue syndrome (ME/CFS) using DNA methylation and micro-RNA expression patterns. This breakthrough distinguishes CFS from other autoimmune and viral conditions, marking a turning point for millions of patients long dismissed by traditional medicine. It's proof that data-driven diagnostics can transform how we understand mystery illnesses. Source: Science Daily — sciencedaily.com/releases/2025/11/251102205021.htm All source links provided for easy reference to the original reporting and research above. This is essential listening for fans of biohacking, hacking human performance, functional medicine, and longevity who want actionable tools from Host Dave Asprey and a guest who embodies what it means to age with energy, clarity, and vitality. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: melatonin heart risk, sleep hormones, microplastics detox, Bryan Johnson, Urolithin A, mitophagy, mitochondrial health, immune aging, DeepMind AI, cellular modeling, omega-3 aggression, neuroinflammation, chronic fatigue biomarker, ME/CFS test, biohacking news, longevity research Thank you to our sponsors! -LYMA | Go to https://lyma.sjv.io/gOQ545 and use code DAVE10 for 10% off the LYMA Laser.-Vibrant Blue Oils | Grab a full-size bottle for over 50% off at https://vibrantblueoils.com/dave. Resources: • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Intro 0:18 — Story 1: Melatonin & Heart Health 1:58 — Story 2: Microplastics Detox 3:39 — Story 3: Urolithin A & Immune Function 5:19 — Story 4: AI Cell Model 6:57 — Story 5: Omega-3 & Aggression 8:43 — Story 6: CFS Blood Test 9:59 — Weekly Upgrade Protocol See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this interview, Róisin McGuigan, Editor, Nucleic Acid Insights, and Jesse Erasmus, Director of Virology at HDT Bio, discuss current challenges and opportunities in RNA safety, manufacturing, and targeted delivery, and the key ongoing obstacles facing viral and LNP-based delivery modalities.
Discover how biotech and healthcare teams are fast-tracking research and development through AI and high-performance cloud infrastructure. Ross Katz sits down with Hugo Shi of Saturn Cloud and Ilya Burkov of Nebius to explore scalable, secure solutions for GPU-heavy AI workloads. From compliance to cost savings, this episode unpacks what it takes to innovate at scale in life sciences. What You'll Learn in This Episode: >> Why AI workloads in biotech demand specialized infrastructure >> How Saturn Cloud and Nebius simplify compliance, scale, and security for life sciences >> Real-world examples of gene editing, RNA sequencing, and medical imaging powered by cloud AI >> The trade-offs between hyperscalers and NeoClouds for GPU availability and cost >> Strategies for deploying, optimizing, and managing large-scale AI models Meet Our Guests Hugo Shi is the CTO and Founder of Saturn Cloud and a co-founder of Anaconda. He brings deep expertise in data science, AI infrastructure, and open-source development, helping teams scale complex workloads with minimal friction. Ilya Burkov is Global Head of Healthcare & Life Sciences Growth at Nebius. With a background in medicine and cloud technology, Ilya leads strategy and partnerships to empower biotech teams with secure, high-performance compute solutions. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Hugo Shi on LinkedIn Connect with IIya Burkov on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.
In this episode of Speaking of Mol Bio, Dr. Andre Ghetti, CEO of AnaBios, offers a deep dive into the world of translational preclinical research. AnaBios is redefining early human insights by using ethically sourced, functional human tissues and cells to generate actionable data before compounds ever enter clinical trials. Ghetti walks us through the company's approach of offering human-relevant safety and efficacy data, validating drug targets, and supporting everything from small startups to major pharma groups.We learn how AnaBios engages with clients to customize assays, especially in high-need areas like non-opioid pain therapies, fibrosis, and cardiac safety, and how they use a blend of standardized and novel functional assays, some of which required building their own hardware. He also discusses their integration of RT-PCR, RNA-seq, and calcium imaging, including genetically encoded sensors to monitor neuronal activity at scale.From their use of machine learning to analyze massive data sets, to collaborations with the FDA, to their unique ability to preserve tissue viability across the U.S., AnaBios offers a powerful glimpse into the future of translational biology. Dr. Ghetti also shares advice for young scientists and reflects on what's next for AnaBios, including oncology and stem-cell model integration. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.
Ερευνητές από τη Βικτώρια, έχουν αναπτύξει το πρώτο φάρμακο τεχνολογίας RNA στον κόσμο, για την «πάθηση του λύκου». Μια αυτοάνοση ασθένεια που επηρεάζει περίπου 20.000 Αυστραλούς. Πρόκειται για μια κρέμα, η οποία χρησιμοποιείται επιδερμικά, προκειμένου να αντιμετωπίσει τα σοβαρά συμπτώματα που προκαλεί η εν λόγω πάθηση, όπως πόνο στις αρθρώσεις, κόπωση και φλεγμονή των κύριων οργάνων.
Broadcast from KSQD, Santa Cruz on 10-30-2025: Dr. Dawn opens with Halloween-themed scary medical stories, beginning with food toxins lurking in refrigerators and pantries. She explains how molds on grains and nuts, particularly Aspergillus species, produce aflatoxins that bind to DNA and cause liver cancer, making peanuts especially risky. Fusarium on wheat produces trichothecenes and fumonisins damaging cell membranes. Penicillium molds on fruits like apples produce patulin creating reactive oxygen species that harm organs. She advises discarding soft moldy foods entirely since fungal hyphae penetrate deeply, while hard cheeses can have moldy portions cut away. Meat spoilage involves bacteria producing cadaverine and putrescine, with E. coli, Campylobacter, Salmonella, and Clostridium causing severe illness through heat-stable toxins. A caller asks about yogurt-covered peanuts tasting rancid and confirms Botox contains botulinum toxin A in different salt forms, used medically for migraines, hyperhidrosis, and strabismus. The caller also describes paper-thin skin on sun-exposed forearms that bleeds easily. Dr. Dawn explains UV radiation damages collagen and elastin, making blood vessels vulnerable to shear forces. She recommends topical vitamin K products like Dermal K and protective lycra sleeves or gardening gauntlets to prevent injuries, emphasizing the need for annual dermatologic exams after extensive sun exposure. An emailer asks about RSV vaccine recommendations before overseas travel. Dr. Dawn disagreed with the couple's physician, citing US Preventive Services Task Force guidelines recommending RSV vaccination for all adults 60 and older, plus those 50+ with chronic conditions. She discusses FDA-approved home testing options including the PIXEL by LabCorp test for COVID, flu, and RSV, and iHealth rapid tests. She notes RSV point-of-care tests are available to medical practitioners and recommends thorough vaccination before international trips. Dr. Dawn presents a frightening investigation into private equity hospital bankruptcies, focusing on Steward Healthcare's 31 hospitals and Prospect's 16 facilities. Private equity firm Cerberus earned $700 million while Steward 650 documented incidents of deficient care including deaths. One woman died from hemorrhage after vendors repossessed equipment due to unpaid bills. She explains the shell game where companies sell hospital land to Medical Properties Trust, forcing new operators to pay rent while private equity extracts profits. The Brookings Institution study reveals systematic prioritization of investor returns over patient care, with courts failing to prevent these practices despite some states passing protective legislation. She discusses stillbirth rates being significantly underreported, with Harvard research showing actual rates of 1 in 147 pregnancies versus CDC's 1 in 175, worsening to 1 in 95 for black families. Over 70% involved known risks like obesity or diabetes, but 30% had no identifiable factors. Dr. Dawn emphasizes unconscious bias in medicine where women's complaints are dismissed, particularly affecting women of color and non-English speakers, noting both patient and provider biases require training to address. Dr. Dawn warns about HPV-related oral squamous cell carcinoma in young men, explaining that changing sexual practices over 30 years have created new transmission routes from genitals to mouth. Major risk factors include smokeless tobacco and hard alcohol which damage DNA. She mentions newly available saliva tests for persistent HPV detection, recommending risk factor reduction for positive cases. She concludes optimistically with a breakthrough Huntington's disease treatment using microRNA molecule AMT-130 delivered via virus to brain striatum. The treatment mirrors toxic Huntington protein's RNA, creating double-stranded structures cells destroy, preventing toxic protein accumulation. The three-year trial of 29 patients showed 75% slowing of disease progression with few side effects, offering hope for 100,000 Americans carrying the mutation, including 40,000 with current symptoms.
Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Download the transcript here
Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Listen to the podcast here
On this week's episode, Daphne Zohar, Bruce Booth, Sam Fazeli, Brian Skorney, Yaron Werber, and Eric Schmidt kick off with market updates, noting that the XBI is showing signs of a sustainable recovery after years of underperformance and highlighting that the IPO market is likely closed for the remainder of the year, but note optimism for early 2026. In deal news, Novartis' $12B acquisition of Avidity is spotlighted as an unprecedented move for a company yet to read out Phase 3 data. The co-hosts also speculate on what this acquisition could mean for Dyne Therapeutics, has a similar RNA-based pipeline in rare muscle disease. Next, Daphne highlights that some of the biggest M&A deals of the year have come from women-led companies - including Avidity. The conversation then shifts to Novo Nordisk's surprise $9Bbid for Metsera, which challenges Pfizer's existing $7.3B deal and raises questions about Novo's intentions. In policy news, manufacturing issues at Novo's Catalent Indiana facility and the impact on the sector are mentioned. The episode concludes with a group discussion around Bruce's lessons from his 20 years in early-stage biotech. *This episode aired on October 31, 2025.
00:47 How bowhead whales live so longResearchers have uncovered a protein that enhances DNA repair and may explain how bowhead whales can live more than 200 years. The protein, cold-induced RNA-binding protein, was shown to enhance repair of double stranded DNA breaks, a particularly troublesome kind of damage. The team showed that this protein could also extend the lives of Drosophila flies and enhance repair in human cells. More needs to be understood about how this protein works, but the researchers hope that it could, one day, help prevent cancer and ageing in humans.Research Article: Firsanov et al.News: This whale lives for centuries: its secret could help to extend human lifespan11:22 Research HighlightsA precise way to grow crystals, with lasers — plus, the specialist organ that allows stinkbugs to protect their eggs from wasps.Research Highlight: How to grow crystals when and where you want themResearch Highlight: Stinkbug ‘ear' actually hosts parasite-fighting fungi13:31 An antivenom against a broad range of snakebitesResearchers have used ‘nanobodies' to create an antivenom that works against 17 snake species' venom. Snakebites kill millions each year, so getting the right antivenom can be life or death. But they are difficult to produce and often are very specific. Now, using nanobodies from llamas, researchers created an antivenom against a broad range of snake species' venom. The new antivenom can now even be produced without the llamas, and the team hope it will pave the way for a more universal antivenom.Research Article: Ahmadi et al.Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.
Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That's the second biggest buy of the year after Johnson & Johnson's January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis' news dropped. The Avidity deal is the latest in an uptick on the pharma M&A front. Also this week, Eli Lilly doubled down on gene therapy with a pick up of Adverum Biotechnologies and its lead program for wet age-related macular degeneration. And Roche, which last month acquired 89bio in a $3.5 billion deal centered on a MASH candidate, said in its third-quarter earnings call on Thursday that more deals could be in the future. Finally, beyond the big guys, Leerink Partners predicts which small- to mid-cap firms might also be on the hunt for new pipeline goodies. Following the dealmaking news, Novartis held its earning call on Tuesday. CEO Vas Narasimhan downplayed the deals Pfizer, AstraZeneca and Amgen have made with the White House, saying they don't address the root of the drug pricing problem President Donald Trump hopes to solve. On other earnings calls, BioMarin announced plans to divest the hemophilia gene therapy Roctavian. Regeneron faced further questions about Eylea and issues with the Catalent plant that's been tripping up its regulatory applications. But the company didn't address last week's news that it was dropping a CAR T asset picked up from 2seventy bio. These are but two of the latest examples of underperforming assets in the cell and gene therapy space. BridgeBio had positive news for patients with limb-girdle muscular dystrophy this week after acing a Phase III trial for an investigational substrate supplementation therapy. Analysts predict the asset could be before the FDA later this year or early next. Finally, with the U.S. government shutdown going on a month, BioSpace takes a look at how the FDA is operating.
Novartis' biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish line. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the $12 billion deal for Avidity in the context of Novartis' recent acquisitions and the antibody-oligonucleotide conjugate platform it is gaining.The team dives into RNA versus DNA modalities, noting antisense and siRNA approaches appear to be gaining traction with major pharmas as traditional gene therapy and gene editing approaches hit rocky times. Still, they note hopeful progress among base editing therapies given the promising early track records of over a dozen base editors in the clinic. They also discuss BioCentury's conversation with base editing inventor David Liu; Alkermes' $2.1 billion acquisition of Avadel; and β-catenin data from Parabilis. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657412#AntibodyOligonucleotideConjugates #RNAtherapeutics #BaseEditing #MuscularDystrophy #WntPathway #BetaCatenin #Orexin2Receptor #PrecisionMedicine00:01 - Sponsor Message: Evotec 02:04 - 12th China Healthcare Summit08:11 - Novartis' $12B Deal16:58 - Alkermes M&A20:01 - David Liu Base Editing25:02 - Parabilis' DataTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This substantial investment underscores Novartis's dedication to expanding its neuroscience portfolio. Avidity's innovative RNA-based therapies show great promise for treating neuromuscular diseases, highlighting a broader industry trend where large pharmaceutical companies are investing heavily in late-stage biotech firms to bolster their pipelines with cutting-edge technologies. Such moves are pivotal as they align with the growing emphasis on precision medicine and the development of novel therapeutic options for conditions with limited existing treatments.In other acquisition news, Eli Lilly has expanded its gene therapy portfolio through acquiring Adverum Biotechnologies for up to $262 million. This acquisition is expected to bolster Eli Lilly's position in the gene therapy space, particularly in ophthalmology. Gene therapy offers transformative potential by directly addressing underlying genetic causes of diseases, with Adverum's focus on ophthalmic conditions potentially offering innovative solutions for unmet medical needs in eye-related disorders. The acquisitions by Novartis and Eli Lilly reflect broader trends within the pharmaceutical industry where companies actively seek to diversify their pipelines through mergers and acquisitions. These transactions emphasize strategic incorporation of advanced biotechnologies such as RNA therapeutics and gene therapy into development portfolios aiming to deliver breakthroughs in patient care.On the regulatory front, Bayer has achieved a milestone with the U.S. FDA approval of Lynkuet (elinzanetant), a nonhormonal medication designed to manage menopause symptoms. This approval represents a significant step forward in providing alternative treatment options to a traditionally hormone-reliant segment, emphasizing the industry's shift towards diversifying therapeutic solutions and addressing unmet medical needs. This move highlights continuous efforts to address women's health issues through new pharmacological interventions.Meanwhile, Merck's Winrevair has received an updated FDA label following successful results from the Phase 3 Zenith trial. This label expansion is anticipated to enhance its market position, potentially propelling Winrevair to blockbuster status. These developments highlight the critical role of rigorous clinical trials in validating drug efficacy and safety, which ultimately influence regulatory decisions and market dynamics.BridgeBio has also made headlines with its successful Phase 3 trial for a rare disease candidate. By demonstrating significant improvements in clinical outcomes and biomarkers, BridgeBio is poised to file for FDA approval. This reflects an increasing focus on precision medicine within the industry, particularly in addressing rare and genetic disorders.In diabetes management news, Innovent and Eli Lilly's mazdutide has outperformed Novo Nordisk's semaglutide in a head-to-head study focused on glucose regulation and weight loss. As a GLP-1/glucagon dual receptor agonist, mazdutide offers broader therapeutic effects, showcasing the competitive landscape in metabolic disorders where novel mechanisms are vying for superiority.Regulatory activities remain pivotal, as demonstrated by Syndax receiving a second indication for its leukemia drug Revuforj. Such expansions underscore the importance of ongoing clinical research and regulatory engagement in maximizing a drug's therapeutic reach.NSupport the show
Varroa mites remain the most destructive pest facing honey bees today—but a revolutionary new treatment may finally shift the balance. In this episode, Jeff Ott and Dr. Becky Masterman welcome Adam Pachl, North American Technical Manager for Bee Health at GreenLight Biosciences, to discuss Norroa, the first EPA-approved dsRNA-based treatment for Varroa mites. Norroa introduces a fundamentally new approach: instead of killing mites outright, it prevents them from reproducing. Adam explains how this RNA interference (RNAi) technology works at the molecular level, blocking the mites' ability to lay viable eggs without harming honey bees or other organisms. He also shares insights from years of field research, including trials across five U.S. states that demonstrated dramatic improvements in colony survival and mite suppression. Becky and Jeff explore the implications of this technology for beekeepers of all scales—from hobbyists managing a few hives to large-scale commercial operations—and how Norroa fits into an integrated pest management strategy. The discussion covers everything from timing of application, compatibility with other treatments, and safety testing, to potential future uses of RNAi against pests like Tropilaelaps. For the first time in decades, beekeepers may have a tool that targets Varroa precisely and safely—without collateral damage to the bees they're fighting to protect. Websites from the episode and others we recommend: GreenLight Biosciences. “GreenLight Biosciences Launches Norroa, the First RNA-Based Treatment for Varroa Mites.” 25 Sep 2025. https://www.greenlightbiosciences.com/articles/greenlight-biosciences-launches-norroa-the-first-rna-based-treatment-for-varroa-mites GreenLight Biosciences. “In the Pipeline: Protecting the Honeybee.” https://www.greenlightbiosciences.com/in-the-pipeline-protecting-the-honeybee GeneOnline. “EPA Registers Norroa as First RNA-Based Treatment for Varroa Mites Threatening Honeybee Populations.” 25 Sept 2025. https://www.geneonline.com/epa-registers-norroa-as-first-rna-based-treatment-for-varroa-mites-threatening-honeybee-populations Honey Bee Obscura Podcast: https://honeybeeobscura.com Project Apis m. (PAm): https://www.projectapism.org Honey Bee Health Coalition: https://honeybeehealthcoalition.org The National Honey Board: https://honey.com Honey Bee Obscura Podcast: https://honeybeeobscura.com Copyright © 2025 by Growing Planet Media, LLC ______________ Betterbee is the presenting sponsor of Beekeeping Today Podcast. Betterbee's mission is to support every beekeeper with excellent customer service, continued education and quality equipment. From their colorful and informative catalog to their support of beekeeper educational activities, including this podcast series, Betterbee truly is Beekeepers Serving Beekeepers. See for yourself at www.betterbee.com This episode is brought to you by Global Patties! Global offers a variety of standard and custom patties. Visit them today at http://globalpatties.com and let them know you appreciate them sponsoring this episode! Thanks to Bee Smart Designs as a sponsor of this podcast! Bee Smart Designs is the creator of innovative, modular and interchangeable hive systems made in the USA using recycled and American sourced materials. Bee Smart Designs - Simply better beekeeping for the modern beekeeper. Give your bees a boost with HiveAlive! Proven to increase bee health, honey yield, and overwinter survival, HiveAlive's unique formula includes seaweed, thyme, and lemongrass, making it easy to feed. Choose from HiveAlive's Fondant Patties, High-Performance Pollen Patties, or EZ Feed Super Syrup—ready-to-use options for busy beekeepers. Buy locally or online. HiveIQ is revolutionizing the way beekeepers manage their colonies with innovative, insulated hive systems designed for maximum colony health and efficiency. Their hives maintain stable temperatures year-round, reduce stress on the bees, and are built to last using durable, lightweight materials. Whether you're managing two hives or two hundred, HiveIQ's smart design helps your bees thrive while saving you time and effort. Learn more at HiveIQ.com. Thanks to Strong Microbials for their support of Beekeeping Today Podcast. Find out more about their line of probiotics in our Season 3, Episode 12 episode and from their website: https://www.strongmicrobials.com Thanks for Northern Bee Books for their support. Northern Bee Books is the publisher of bee books available worldwide from their website or from Amazon and bookstores everywhere. They are also the publishers of The Beekeepers Quarterly and Natural Bee Husbandry. _______________ We hope you enjoy this podcast and welcome your questions and comments in the show notes of this episode or: questions@beekeepingtodaypodcast.com Thank you for listening! Podcast music: Be Strong by Young Presidents; Epilogue by Musicalman; Faraday by BeGun; Walking in Paris by Studio Le Bus; A Fresh New Start by Pete Morse; Wedding Day by Boomer; Christmas Avenue by Immersive Music; Red Jack Blues by Daniel Hart; Original guitar background instrumental by Jeff Ott. Beekeeping Today Podcast is an audio production of Growing Planet Media, LLC ** As an Amazon Associate, we may earn a commission from qualifying purchases Copyright © 2025 by Growing Planet Media, LLC
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show
Upgrade your biology in 10 minutes with this week's rundown from Dave Asprey. This episode breaks down the five biggest stories in biohacking and health-tech — from genetic rejuvenation to your future digital twin — giving you the tools to live longer, perform better, and stay ahead of the curve.This episode covers:• Vitamin D as the Surprising “Anti-Aging Pill”A new five-year randomized study shows that daily 2,000 IU vitamin D supplementation slowed telomere shortening by 140 base pairs compared to placebo, translating to measurable gains in biological youth. Vitamin D isn't just for bones anymore — it's a foundational longevity molecule.Source: Science Daily — https://www.sciencedaily.com/releases/2025/10/251022023132.htm• The Supercentenarian Gene That Rejuvenates Old HeartsResearchers at the University of Bristol identified a gene variant, LAV-BPIFB4, common among people living past 100, that reversed cardiac aging in animal studies — restoring blood flow, heart strength, and tissue repair with a single treatment. It's a glimpse into how gene therapy could soon democratize superhuman longevity.Source: University of Bristol News — https://www.bristol.ac.uk/news/2025/october/progeria.html• FDA Closes the “GRAS” Loophole — Supplements Enter a New EraThe FDA just ended decades of self-certification for new dietary ingredients, requiring full agency review for anything entering the market. It's the biggest shakeup in supplement regulation in years — raising quality, accountability, and trust across the entire industry.Source: Mintz FDA Flux Newsletter — https://www.mintz.com/insights-center/viewpoints/2791/2025-10-16-fda-flux-october-2025-newsletter• Microbes That Trigger Autophagy — Your Gut as an Anti-Aging SwitchScientists at the University of Basel discovered that certain dietary bacteria containing double-stranded RNA can directly trigger autophagy, the body's built-in cell-recycling system. Fermented foods like kimchi, kefir, and sauerkraut may now be proven longevity tools for activating repair from the inside out.Source: University of Basel — https://www.unibas.ch/en/News-Events/News/Uni-Research/Longevity-research—Dietary-stress-supports-healthy-aging.htmlFurther reading: Neuroscience News — https://neurosciencenews.com/dietary-rna-cellular-aging-29757/• Your Medical Avatar Is Coming — The Digital Twin of YouForbes reports on the rise of personalized “medical avatars” — AI-powered digital twins built from your wearables and biometrics that can predict health risks, recommend interventions, and evolve alongside your biology. Doctors like Daniel Kraft call it generative health — a revolution in predictive medicine where your data literally becomes your doctor.Source: Forbes Innovation — https://www.forbes.com/sites/johnwerner/2025/10/21/wearables-ai-and-your-personal-medical-avatar/This is essential listening for fans of biohacking, human performance, functional medicine, and longevity sciencewho want real, actionable tools from Dave Asprey — the father of biohacking and founder of Bulletproof Coffee.With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your lifespan, and upgrade every system in your body and mind.New episodes drop every Tuesday, Thursday, Friday, and Sunday. Dave asks the questions no one else will — and gives you the science-backed tools to become stronger, smarter, and more resilient.Keywords: vitamin D longevity, telomeres, BPIFB4 gene, cardiac rejuvenation, supplement regulation, GRAS FDA, autophagy, microbiome, fermented foods, biohacking news, medical avatar, digital twin, predictive medicine, Daniel Kraft, quantum health, wearable AI, Dave Asprey, The Human UpgradeThank you to our sponsors! TRU KAVA | Go to https://trukava.com/ and use code DAVE10 for 10% off.HeartMath | Go to https://www.heartmath.com/dave to save 15% off.Timestamps: 0:00 — Introduction0:18 — Story 1: Vitamin D & Telomeres1:02 — Story 2: Longevity Gene Therapy1:49 — Story 3: FDA Supplement Reform2:38 — Story 4: Gut Bacteria & Autophagy3:46 — Story 5: Medical Avatars4:53 — Weekly Protocol5:42 — OutroSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
2024 年的诺贝尔化学奖是颁给了三位在蛋白质结构预测和蛋白质设计领域作出开创性贡献的科学家。这标志着 AI 已经成为生命科学的核心工具 ，正在改变我们理解生命的方式和重塑药物研发的未来。 我们今天的嘉宾是深圳湾实验室的周耀旗教授，他是这场变革的亲历者和推动者之一。他最初在学术界专注于蛋白质结构预测，后来他敏锐地意识到 RNA 领域的潜力与挑战，将研究方向转向 RNA 结构预测。现在他又走上创业之路，带领团队开发 以 RNA 为靶点的小分子药物，探索如何将基础研究真正转化为新的疗法。今天的节目我们聊一聊作为蛋白质结构预测工具的 AlphaFold3，它的突破与局限在哪里？RNA为什么是新一代药物的重要靶点？以及 AI 在新药研发中的作用究竟是什么? 本期人物 周耀旗，深圳湾实验室资深研究员，砺博生物科学创始人 Yaxian，「科技早知道」主播 主要话题 [02:42] 为什么蛋白质结构如此重要？解析蛋白结构是理解生命机器的关键 [05:47] 蛋白质结构预测简史（超硬核）：基于模板 --> 碎片拼接 --> 二面角+距离预测 [14:26] 「1+2=3」：AlphaFold 革命性飞跃的背后 [17:40] 结构生物学家会不会被替代？聊聊 AlphaFold 还做不了的事 [23:26] RNA 结构预测为何更难？仅4个碱基，结构不稳定，已知数据稀缺 [29:24] 蛋白质只是「提线木偶」，RNA 才是「操纵者」 [31:56] 从靶向蛋白到靶向 RNA -- HIV蛋白酶抑制剂的成功和 KRAS 蛋白的「光滑锁眼」的难题 [35:49] 靶向 RNA 药物的里程碑：首个靶向 RNA 的小分子药利司扑兰（Risdiplam） [38:50] 在缺乏结构数据的情况下，如何开发靶向 RNA 的药物？ [43:06] AI 在新药研发中的真实作用：是加速器，而非革命 [45:39] AI for Science：摆脱数据依赖，回归物理，寻找分子世界的「牛顿定律」 延伸阅读 AlphaFold 由谷歌 DeepMind 开发的人工智能程序，AlphaFold2 在精准预测蛋白质三维结构方面取得革命性突破而闻名。AlphaFold3 将其能力扩展到了 RNA、DNA 等更多分子。 CASP (Critical Assessment of protein Structure Prediction) 国际蛋白质结构预测竞赛，每两年举办一次，是评估和检验全球结构预测方法水平的「奥林匹克」 KRAS 一种重要的信号蛋白，其基因突变是多种癌症（如胰腺癌、肺癌）的关键驱动因素。由于其蛋白质表面光滑，缺乏明显的结合位点，长期以来被认为是「不可成药」的靶点。 SMN 蛋白 (Survival of Motor Neuron protein) 即运动神经元存活蛋白，该蛋白的缺失会导致 脊髓性肌萎缩症 (SMA)。全球首个靶向 RNA 的药物就是通过调控 SMN 的 RNA 来提高其蛋白水平。 PCC (Pre-clinical Candidate) 即临床前候选化合物，指在早期发现阶段后，被选定进入正式的临床前研究（如动物安全性、药代动力学试验）的药物分子 幕后制作 监制：Yaxian 后期：迪卡 运营：George 设计：饭团 商业合作 声动活泼商业化小队，点击链接直达声动商务会客厅（https://sourl.cn/9h28kj ），也可发送邮件至 business@shengfm.cn 联系我们。 加入声动活泼 声动活泼目前开放商务合作实习生、社群运营实习生和 BD 经理等职位，详情点击招聘入口详情点击招聘入口 (https://eg76rdcl6g.feishu.cn/docx/XO6bd12aGoI4j0xmAMoc4vS7nBh?from=from_copylink) 关于声动活泼 「用声音碰撞世界」，声动活泼致力于为人们提供源源不断的思考养料。 我们还有这些播客：声动早咖啡 (https://www.xiaoyuzhoufm.com/podcast/60de7c003dd577b40d5a40f3)、声东击西 (https://etw.fm/episodes)、吃喝玩乐了不起 (https://www.xiaoyuzhoufm.com/podcast/644b94c494d78eb3f7ae8640)、反潮流俱乐部 (https://www.xiaoyuzhoufm.com/podcast/5e284c37418a84a0462634a4)、泡腾 VC (https://www.xiaoyuzhoufm.com/podcast/5f445cdb9504bbdb77f092e9)、商业WHY酱 (https://www.xiaoyuzhoufm.com/podcast/61315abc73105e8f15080b8a)、跳进兔子洞 (https://therabbithole.fireside.fm/) 、不止金钱 (https://www.xiaoyuzhoufm.com/podcast/65a625966d045a7f5e0b5640) 欢迎在即刻 (https://okjk.co/Qd43ia)、微博等社交媒体上与我们互动，搜索 声动活泼 即可找到我们。 期待你给我们写邮件，邮箱地址是：ting@sheng.fm 声小音 https://files.fireside.fm/file/fireside-uploads/images/4/4931937e-0184-4c61-a658-6b03c254754d/gK0pledC.png 欢迎扫码添加声小音，在节目之外和我们保持联系。 Special Guest: 周耀旗.
Next-generation platforms and technologies are getting closer to cracking one of biopharma's biggest problems: delivering medicines, and mAbs in particular, to the brain. On the latest BioCentury This Week podcast, BioCentury's Selina Koch details the latest innovations in blood-brain-barrier shuttles and how the technologies could transform the treatment of neurological diseases.BioCentury's Lauren Martz discusses her conversation with Tony Wood, CSO of GSK, which included the pharma's strategy for indication expansion, why it prefers RNA modalities over AAV-based gene therapies, and how its quest for causal biology has evolved over the years.Washington Editor Steve Usdin discusses the first set of FDA's new commissioner's national priority review vouchers, and why the voucher program is unlikely to function as an incentive capable of steering future behavior. Usdin also discusses the potential impact of FDA staffing reductions on the sector. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657326#BloodBrainBarrier #Neurology #DrugDelivery #MonoclonalAntibodies #RNAtherapeutics #CausalBiology #FDA00:01 - Sponsor Message: Evotec01:57 - Brain Shuttles13:57 - GSK Q&A20:08 - FDA VouchersTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Más de dos mil mexicanos detenidos en EU desde el inicio de Trump Beca Universal Rita Cetina llegará a todas las primarias públicas en 2026Tormenta tropical Melissa se forma en el AtlánticoMás información en nuestro podcast
First up on the podcast, Contributing Correspondent Kai Kupferschmidt takes a trip to Svalbard, an Arctic archipelago where ancient RNA viruses may lie buried in the permafrost. He talks with host Sarah Crespi about why we only have 100 years of evolutionary history for viruses such as coronavirus and influenza, and what we can learn by looking deeper back in time. Next on the show, Nathalie Stroeymeyt, senior lecturer at the School of Biological Sciences at the University of Bristol, joins freelancer producer Elah Feder to talk about how humans aren't the only species that takes public health measures to stop outbreaks. To keep their colonies healthy when threatened with infectious disease, ants socially distance and even make architectural changes to their nests' organization. This week's episode was produced with help from Podigy. About the Science Podcast Learn more about your ad choices. Visit megaphone.fm/adchoices
First up on the podcast, Contributing Correspondent Kai Kupferschmidt takes a trip to Svalbard, an Arctic archipelago where ancient RNA viruses may lie buried in the permafrost. He talks with host Sarah Crespi about why we only have 100 years of evolutionary history for viruses such as coronavirus and influenza, and what we can learn by looking deeper back in time. Next on the show, Nathalie Stroeymeyt, senior lecturer at the School of Biological Sciences at the University of Bristol, joins freelancer producer Elah Feder to talk about how humans aren't the only species that takes public health measures to stop outbreaks. To keep their colonies healthy when threatened with infectious disease, ants socially distance and even make architectural changes to their nests' organization. This week's episode was produced with help from Podigy. About the Science Podcast Learn more about your ad choices. Visit megaphone.fm/adchoices
DNA doesn't “do", it instructs. In this episode of the Jack Westin MCAT Podcast, Mike and Molly walk through the central dogma, how we go from DNA → RNA → protein—and the regulation that makes different cells, well, different. Perfect for MCAT Bio/Biochem: we hit transcription, RNA processing, translation mechanics (A–P–E sites), start/stop codons, eukaryote vs. prokaryote differences, and multi-layered gene expression regulation (chromatin, transcription factors, miRNA/siRNA, ubiquitin, & more).
RNA is easier to detect and points toward cancer activity better than DNA testing, a recent study concludes. Johns Hopkins Kimmel Cancer Center director William Nelson says there's an even more accurate method on the horizon. Nelson: Will RNA sequencing … Will RNA based tests form the basis for cancer screening and monitoring? Elizabeth Tracey reports Read More »
Using blood tests to look for cancer and cancer recurrence has been an area of active research for some time now, with a new study pointing to RNA rather than DNA for detection. William Nelson, director of the Kimmel Cancer … Can RNA provide a way to look for cancer recurrence? Elizabeth Tracey reports Read More »
rWotD Episode 3084: RsaOG Welcome to random Wiki of the Day, your journey through Wikipedia's vast and varied content, one random article at a time.The random article for Monday, 13 October 2025, is RsaOG.RsaOG (an acronym for RNA S. aureus Orsay G) is a non-coding RNA that was discovered in the pathogenic bacteria Staphylococcus aureus N315 using a large scale computational screening based on phylogenetic profiling. It was first identified, but not named, in 2005. RsaOG has since been identified in other strains of Staphylococcus aureus under the name of RsaI, it has also been discovered in other members of the Staphylococcus genus (such as Staphylococcus carnosus) but in no other bacteria.The RsaOG gene is conserved in all Staphylococcaceae sequenced genomes, its secondary structure contains two highly conserved unpaired sequences which have the ability to form a pseudoknot. Northern blot experiments show that RsaOG is expressed in several S. aureus strains. Mapping of RsaOG ends indicates a size of 146 nucleotides in S. aureus. RsaOG ncRNA is thought to have trans-acting regulatory functions, possibly on fine tuning toxin production or aiding with invasion.This recording reflects the Wikipedia text as of 01:11 UTC on Monday, 13 October 2025.For the full current version of the article, see RsaOG on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Bluesky at @wikioftheday.com.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm long-form Patrick.
A little over a week ago, I spoke with Kevin McKernan about the paper he co-authored with Jessica Rose and David Speicher, looking at DNA contamination, including SV40 promoter-enhancer sequences, in the Pfizer and Moderna Covid vaccines. In that episode, I asked Kevin whether the paper is enough to demonstrate fraud on the part of the vaccine manufacturers. This is important, because if fraud can be shown, these companies lose their protection from legal liability.In this episode, I speak with Dr. Jessica Rose about the paper. She explains what is needed to prove fraud, and why that is challenging, but also explains why there is a strong case for it. We also talk about the corrupt nature of the justice system, her own calculation of VAERS underreporting, and the preprint by Kevin McKernan that had just come out, showing "Hyperstimulatory N⁶-methyladenine (m6A) in residual SV40 plasmid DNA in mRNA vaccines"—and possibly more evidence of fraud.We also talk a little about the meaning of life, and Jessica's cat shows up near the end. Again, the paper is here.Jessica's lay-person write-up of the paper is here.You can find Jessica on Substack, and on X.I spoke with Jessica back in May, about self-amplifying RNA.And my episode with Kevin, about the DNA contamination, is here.
Send us a textIn this episode of the Life Science Success Podcast my guest is Byron Purse, co-founder of AlidaBio and professor of chemistry at San Diego State University who is pioneering innovative approaches to studying RNA modifications. Byron brings a wealth of expertise in synthetic and natural nucleic acid modifications, with a passion for advancing biotechnology and human health through his groundbreaking research and entrepreneurial endeavors.00:00 Introduction to Life Science Success Podcast00:29 Meet Byron Purse: Professor and Co-Founder of AlidaBio01:05 Byron's Journey into Life Sciences03:10 From Academia to Entrepreneurship06:49 Founding AlidaBio: Vision and Mission08:59 Innovations in RNA Modifications23:09 Challenges and Successes in Developing the EpiPlex™ Platform28:44 Leadership and Inspiration35:00 Concerns and Future Outlook in Life Sciences43:02 Conclusion and Final Thoughts
Blaise Agüera y Arcas's talk took us on a journey through What is Intelligence?, his groundbreaking new work connecting the evolutionary dots between life, computation, and symbiogenesis. He explores how, in our symbiotic world, things combine to make larger things all the time. We might think of humanity in terms of the individual — but we're already part of everything we're creating, which is in turn co-creating us. In the story of technology and humanity, are we distinct from the technologies that we make? Agüera y Arcas' cuts through the essentialist dogma with a functionalist view: Biological computing — computation through DNA, RNA, and proteins — is not a strange outcropping of life but its very nature. Blaise Agüera y Arcas is a VP and Fellow at Google, where he is the CTO of Technology & Society and founder of Paradigms of Intelligence (Pi). Pi is an organization working on basic research in AI and related fields, especially the foundations of neural computing, active inference, sociality, evolution, and artificial life. During his tenure at Google, Blaise has innovated on-device machine learning for Android and Pixel; invented Federated Learning, an approach to decentralized model training that avoids sharing private data; and founded the Artists + Machine Intelligence program.
Detectable HIV-1 RNA (viral load) can seem very worrisome for people living with HIV who are receiving antiretroviral therapy (ART) and for their healthcare professionals. Tune in to learn how Brian R. Wood, MD, differentiates HIV-1 RNA “blips” from persistent low-level viremia and from virologic failure, and how he handles each scenario.Presenter:Brian R. Wood, MDProfessor of MedicineDivision of Allergy and Infectious DiseasesUniversity of WashingtonSeattle, WashingtonLink to full program: https://bit.ly/4nS7rYEGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This episode is sponsored by AGNTCY. Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support. Can AI and RNA testing make illness optional? In this episode, Eye on AI host Craig S. Smith sits down with Naveen Jain, founder and CEO of Viome, to explore how RNA sequencing and artificial intelligence are transforming our understanding of chronic disease. Jain shares how a personal tragedy led him to launch Viome, a company on a mission to digitize the human body, predict illness before symptoms appear, and revolutionize healthcare. Together they discuss how Viome uses metatranscriptomics to analyze microbiome and human gene expression, what makes RNA a better indicator of health than DNA, and how large molecular AI models are paving the way for early detection of cancer, diabetes, Alzheimer's, and more. Jain also reveals his bold entrepreneurial framework—“Why this, why now, why me?”—and his belief that asking better questions is the real key to innovation. If you're interested in the intersection of AI, biotechnology, and human longevity, this is an episode you won't want to miss. Stay Updated: Craig Smith on X:https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI
Zakalený vzhled piva souvisí s kombinací proteinů z ječmene a polyfenolů z chmele. Když vědci přidali do ležáků extrakt z kvasinek navíc, pivo se nesrazilo. Roli v tom hraje spojení proteinů a kvasinkové RNA.
Impact Video Ministries explains to us how we can know that god is real, and they are mostly length based reasons.Cards:Fact-Checking James Tour's Embarrassing Debate Performance:www.youtube.com/watch?v=YAm2W99Qm0oGod's "Perfect" Word has a LOT of Imperfections…:https://www.youtube.com/watch?v=_TVKrUWbvXQDesigns Need Designers, so EVERYTHING Is Designed!: https://www.youtube.com/watch?v=hPDm77oAXXUOriginal Video: https://tinyurl.com/2cyaq6djSources:Neutrino detector: https://tinyurl.com/hwlcvcqAbiogenesis through gradual evolution of autocatalysis into template-based replication: https://tinyurl.com/2359v3qaIdentifying the wide diversity of extraterrestrial purine and pyrimidine nucleobases in carbonaceous meteorites: https://tinyurl.com/yyqbrajwLife as a manifestation of the second law of thermodynamics: https://tinyurl.com/29fqxpgsOrganic Synthesis via Irradiation and Warming of Ice Grains in the Solar Nebula: https://tinyurl.com/262ln3vyOrigin and evolution of the genetic code: the universal enigma: https://tinyurl.com/28fp5xu4Spontaneous formation and base pairing of plausible prebiotic nucleotides in water: https://tinyurl.com/2c2n655rSpontaneous network formation among cooperative RNA replicators: https://tinyurl.com/ycwk6s3rThe Genetics of Vitamin C Loss in Vertebrates: https://tinyurl.com/224hum2aWhere did bone come from? An overview of its evolution: https://tinyurl.com/24w9azexThe human cell count and size distribution: https://tinyurl.com/2d2qsq3lWhat is the Most Recent Manuscript Count for the New Testament?: https://tinyurl.com/28kcvamgAll my various links can be found here:http://links.vicedrhino.comThis content is CAN credentialed, which means you can report instances of harassment, abuse, or other harm on their hotline at (617) 249-4255, or on their website at creatoraccountabilitynetwork.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/viced-rhino-the-podcast--4623273/support.
In this episode of the Epigenetics Podcast, we talked with Mo Motamedi from the Center for Cancer Research at Massachusetts General Hospital about his work on RNA-mediated epigenetic regulation. The Interview starts with Dr. Motamedi sharing his personal journey into the realm of biology, sparked by a familial inclination towards science and a challenge to excel in a field that initially felt daunting. His passion was ignited during a genetics class, as he recognized the quantitative nature of the discipline amidst the evolution of modern techniques like qPCR and high-throughput sequencing. Dr. Motamedi goes on to articulate the importance of understanding the interplay between genetics and broader biological systems, emphasizing that an insightful grasp of evolution is vital for decoding cellular mechanisms. He reflects on his time in a postdoctoral lab under Danish Moazet, investigating RNA interference (RNAi) and its unexpected nuclear roles, contributing significantly to the understanding of how RNAi is involved in gene silencing via chromatin interaction. As his narrative unfolds, Dr. Motamedi provides deep insights into his own lab's work, which focuses on the establishment and maintenance of epigenetic states and their implications in cancer epigenetics. He discusses groundbreaking discoveries related to RNAi and heterochromatin, detailing experiments that unveil how specific proteins contribute to transcriptional and post-transcriptional gene silencing. A pivotal theme emerges: the complex dynamics of genome evolution and chromatin organization can be reshaped under various biological contexts, including the quiescent state of cells under stress. Moreover, the discussion traverses recent publications from Dr. Motamedi's lab, revealing how they identify long non-coding RNAs that function as silencers at centromeres, an essential mechanism that aids in the establishment of heterochromatin independently of RNAi. His findings advocate for the idea that well-structured genome organization can lead to more efficient gene regulation, which can also be crucial in therapeutic contexts for various cancers. References Motamedi, M. R., Hong, E. J., Li, X., Gerber, S., Denison, C., Gygi, S., & Moazed, D. (2008). HP1 proteins form distinct complexes and mediate heterochromatic gene silencing by nonoverlapping mechanisms. Molecular cell, 32(6), 778–790. https://doi.org/10.1016/j.molcel.2008.10.026 Joh, R. I., Khanduja, J. S., Calvo, I. A., Mistry, M., Palmieri, C. M., Savol, A. J., Ho Sui, S. J., Sadreyev, R. I., Aryee, M. J., & Motamedi, M. (2016). Survival in Quiescence Requires the Euchromatic Deployment of Clr4/SUV39H by Argonaute-Associated Small RNAs. Molecular cell, 64(6), 1088–1101. https://doi.org/10.1016/j.molcel.2016.11.020 Joh, R. I., Lawrence, M. S., Aryee, M. J., & Motamedi, M. (2021). Gene clustering drives the transcriptional coherence of disparate biological processes in eukaryotes. Systems Biology. https://doi.org/10.1101/2021.04.17.440292 Related Episodes Evolutionary Forces Shaping Mammalian Gene Regulation (Emily Wong) Chromatin Evolution (Arnau Sebé-Pedrós) The Role of lncRNAs in Tumor Growth and Treatment (Sarah Diermeier) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com
Słuchasz nas regularnie? Zajrzyj na https://patronite.pl/radionaukowe***Ze szkoły mniej więcej pamiętamy obrazek: obszerna komóreczka otoczona błoną, w środku jądro, jakieś mitochondrium, całość pływa wygodnie w cytoplazmie. To oczywiście uproszczone przedstawienie. Podstawowa zmiana jest taka, że w komórkach nic wygodnie nie pływa: elementów jest bardzo dużo i są ciasno upchane. Ma to swoją funkcję. – Dzięki temu różne cząsteczki mogą ze sobą w uporządkowany sposób oddziaływać – wyjaśnia gość odcinka, dr Takao Ishikawa z Wydziału Biologii Uniwersytetu Warszawskiego. – Współczesne badania pokazują, że w komórce jest bardzo, bardzo tłoczno – dodaje. Rozmawiamy o niesamowicie złożonym i dopracowanym ewolucyjnie mechanizmie, jakim jest komórka.W jądrze komórkowym informacja genetyczna zostaje poddana transkrypcji, czyli przepisana na cząsteczki RNA. Nieduży fragment DNA rozwija się, przepisuje do RNA i zwija z powrotem. – Zapis genetyczny w każdej komórce w zasadzie jest taki sam, ale w zależności od tego, w jakiej tkance dana komórka się znajduje, to stopień superskrętów w różnych obszarach materiału genetycznego może być różny, co się przekłada właśnie na to, że różne geny są aktywne w jednej tkance, a inne w drugiej tkance – tłumaczy mój gość. Cząsteczki mRNA wydostają się z jądra komórkowego i trafiają do rybosomów, gdzie stykają się z innym rodzajem RNA: transferowym, tRNA. W rybosomie poszczególne aminokwasy łączą się w łańcuch białkowy, który odzwierciedla informację genetyczną. Komórki bowiem na co dzień są bardzo zajęte produkowaniem białek.W odcinku omawiamy też oczywiście pozostałe elementy komórki, a jest ich sporo. Będzie o błonie komórkowej, mitochondriach, retikulum i aparacie Golgiego. Dowiecie się też, jaka komórka w ludzkim ciele jest największa, a jaka najmniejsza, dlaczego nie do końca da się stworzyć sztuczną komórkę do badań i skąd wiemy, że mitochondria mają pochodzenie bakteryjne. Posłuchajcie, zachwycicie się swoim organizmem!
In today's episode, we had the pleasure of speaking with Stephen Liu, MD, about the use of tepotinib (Tepmetko) in patients with metastatic non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. In our exclusive interview, Dr Liu discussed key efficacy and safety findings from the phase 2 VISION trial (NCT02864992) that led to the FDA approval of tepotinib for this indication; the comparable response rates seen between tissue and liquid biopsy results, as well as across NSCLC treatment lines; and the importance of early biomarker testing, including RNA sequencing, to identify actionable mutations and optimize treatment.
Rebecca Culshaw Smith's Substack, “The Real AIDS Epidemic,” highlights core criticisms of mainstream HIV/AIDS theory, medical testing, pharmaceutical practices, and challenges to scientific orthodoxy. Based on her popular posts, interviews, and thematic content, these are 20 of the most important ideas advanced on her platform: 1. Questioning the existence of HIV as a unique virus, arguing that classic virological isolation (Koch's postulates) has not been fulfilled. 2. Highlighting the non-specificity and cross-reactivity of HIV antibody tests, leading to potential misdiagnosis. 3. Criticism of “viral load” PCR tests for not detecting whole pathogens but only RNA fragments. 4. Noting the shifting criteria for HIV test positivity over time, calling diagnostic standards into question. 5. Documenting long-term “non-progressors” and “elite controllers” who remain healthy without antiretroviral therapy. 6. Raising awareness of AIDS-defining illnesses in HIV-negative individuals and questioning causality. 7. Arguing that hazard from AIDS medications (e.g., AZT, Truvada, Prep) may outweigh their benefits, especially due to their toxicity and inconsistent trial results. 8. Critique of the marketing and deployment of pre-exposure prophylaxis (Prep), calling it a pharmaceutical “scandal” targeting people not at significant risk. 9.Exploring how COVID-19 public health narratives mirror what she views as deception and fear tactics from the AIDS era. 10. Disputing the epidemiological narrative that AIDS is globally caused by a single infectious agent, and highlighting massive regional/demographic inconsistencies. 11. Exposing groupthink, censorship, and reputational shaming used against scientists questioning the HIV/AIDS paradigm. 12. Emphasizing failures of antiretroviral therapy in preventing disease progression for many patients. 13.. Explaining the statistical and mathematical problems in foundational HIV/AIDS research and the “shaky foundation” of guiding studies. 14. Arguing that AIDS-defining diseases may often reflect toxicity, malnutrition, or existing comorbidities, not a distinct viral syndrome. 15. Linking historical and social factors (such as drug use, pharmaceutical incentives) to the creation and persistence of the HIV/AIDS establishment. 16. Alerting readers to issues of false positive antenatal screening and broader concerns about mass diagnostic testing in medicine. 17. Suggesting that “virus-like particles” in the body are misidentified as pathogens, not proof of HIV's existence. 18. Forecasting that advances in AI and technology may help overturn scientific “consensus” by increasing transparency and debate. 19 Publicly refuting hit pieces and attempts to “cancel” her work as ideological suppression, not science. 20.Advocating for a return to fundamental scientific rigor and genuine skepticism in medical research, especially around virology and public health narratives. These topics synthesize her core objections to HIV/AIDS orthodoxy and frame her Substack as a point of dissent and critique against modern medical paradigms and their social consequences.
Listen & subscribe on Apple, Spotify, YouTube, and other platforms. Welcome everyone to the weekly San Diego Tech News! I'm Neal Bloom from Rising Tide Partners and the Tacos and Tech Podcast. My co-host in this episode is Fred Grier, journalist and author of The Business of San Diego substack. He covers the ins-and-outs of the startup world including breaking news, IPOs, fundraising rounds, and M&A through his newsletter. Before we dive in, we wanted to thank and ask our listeners to help us grow the show, leave a review and share with one other person who should be more plugged in with the SD Tech Scene. Thank you for the support and for helping us build the San Diego Startup Community! 9/19 Broader Defense Tech: Harpoon x Firestorm Mixer Debrief El Segundo Defense Tech Mixer Debrief Firestorms Labs opens 60,000 SFT Facility in Mira Mesa Biotech: Treeline Biosciences emerges from stealth with $200M backed by ARCH Venture. Arnatar Therapeutics focused on precision RNA therapies emerges from stealth. Debut Bio raises and expands to Asia Yatiri - acquired another startup Luna Diabetes raises a Series A Curated Events List – For full list – check The Social Coyote Sept 26 - Defense Tech Gathering Oct 3-5 Startup Weekend Oct 6-10 SD Startup Week
Breastmilk is Dynamic Cellular and transcriptional diversity over the course of human lactation This recent 2022 paper in the Proceedings of the National Academy of Sciences by Dr. Nyqiust and colleagues is a site for sore eyes. It offers a remarkable, high-resolution portrait of how the cellular landscape of human breast milk (hBM) shifts over time. The authors capture something both scientifically rich and uniquely human: the dynamic, living composition of milk as it adapts to the changing needs of mother and child. The abstract: "Human breast milk is a dynamic fluid that contains millions of cells, but their identities and phenotypic properties are poorly understood. We generated and analyzed single-cell RNA-sequencing (scRNA-seq) data to characterize the transcriptomes of cells from hBM across lactational time from 3 to 632 d postpartum in 15 donors. We found that the majority of cells in hBM are lactocytes, a specialized epithelial subset, and that cell-type frequencies shift over the course of lactation, yielding greater epithelial diversity at later points. Analysis of lactocytes reveals a continuum of cell states characterized by transcriptional changes in hormone-, growth factor-, and milk production-related pathways. Generalized additive models suggest that one subcluster, LC1 epithelial cells, increases as a function of time postpartum, daycare attendance, and the use of hormonal birth control. We identify several subclusters of macrophages in hBM that are enriched for tolerogenic functions, possibly playing a role in protecting the mammary gland during lactation. Our description of the cellular components of breast milk, their association with maternal–infant dyad metadata, and our quantification of alterations at the gene and pathway levels provide a detailed longitudinal picture of hBM cells across lactational time. This work paves the way for future investigations of how a potential division of cellular labor and differential hormone regulation might be leveraged therapeutically to support healthy lactation and potentially aid in milk production." (Nyquist et. al. 2022) And more information on breastmilk immunology and a recipe. Dr. M
© 2020-2025 Ivy Podcast Discovery LLC
